Physician profile
Sharon Y Hook
NPI 1255361911
$933,855.60
in general payments reported to CMS, 2019-2025
8 companies · $137K in 2025
The $137K reported for 2025 was more than what 99% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151K · 2020: $159K · 2021: $177K · 2022: $111K · 2023: $68K · 2024: $132K · 2025: $137K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $303K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $303,220.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $331,700.00 | 2019-2023 | Allocate |
| Axogen | $226,206.60 | 2019-2025 | Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Cap |
| Rti Surgical, INC | $217,529.00 | 2020-2025 | |
| Surgalign Spine Technologies, INC. | $65,740.00 | 2019-2020 | |
| Biowound Solutions, INC. | $42,000.00 | 2024-2025 | Bio-Connekt |
| Biotissue Holdings INC. | $28,080.00 | 2024 | |
| Organogenesis INC. | $17,300.00 | 2025 | Apligraf, Novachor, Nushield |
| Merakris Therapeutics, INC. | $5,300.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Hook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.